What drives today's volume in IDIA.SW stock?

Today's volume is driven by clinical and partner updates, plus pre-earnings positioning. A recent report on a partner trial success and Idorsia’s licensing ties are pulling trader interest ahead of the **2026-02-26** earnings date.

How should I read Meyka AI's IDIA.SW stock grade?

Meyka AI rates IDIA.SW **68.47** out of 100 (Grade B, HOLD). The grade weights sector comparison, growth, metrics and forecasts. It is informational only and not a substitute for personal research or advice.

What price target does Meyka AI give for IDIA.SW stock?

Meyka AI's forecast model projects **CHF 5.62** for 12 months and **CHF 9.89** in three years, implying roughly **+63.95%** from the current **CHF 3.43**. Forecasts are model-based projections and not guarantees.

What are the main risks for IDIA.SW stock?

Primary risks are failed clinical trials, delayed commercialization and cash burn. Market sensitivity is high given Idorsia’s biotech profile, so news events can cause significant short-term volatility for IDIA.SW stock.

CH Stocks

IDIA.SW Idorsia Ltd (SIX) pre-market CHF 3.43 most active: volume 880,472

ByDanny Kontos January 21, 2026

IDIA.SW stock is trading pre-market at CHF 3.43, with 880472.00 shares changing hands and a small intraday move of -0.58%. Volume is the key story: Idorsia (IDIA.SW) is among the most active names on the SIX this session, drawing attention ahead of a late-February earnings announcement and upcoming clinical readouts. We examine price action, fundamentals and technical signals to explain why traders are focused on Idorsia and what the next catalysts could mean for holders and active traders.